The topical calcineurin inhibitors pimecrolimus and tacrolimus have been demonstrated to be an effective new anti-inflammatory therapy. The only clinically relevant side-effect reported is transient application site burning and stinging itch at the beginning of topical therapy.
Department of Dermatology and Boltzmann Institute for Immuno- and Cell Biology of the Skin, University of Münster, Von-Esmarch-Strasse 58, Münster, Germany. sonja.staender@uni-muenster.de
